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ABSTRACT
Cytomegalovirus reactivation and infection post-allogeneic hematopoietic stem cell transplant continue to
cause morbidity and mortality. Current pharmacologic therapies are limited by side effects. Adoptive
transfer of ex vivo generated cytomegalovirus-specific T cells has the potential to restore immunity,
prevent cytomegalovirus, and circumvent the need for pharmacologic therapies. We have generated
donor-derived cytomegalovirus-specific cytotoxic T cells using dendritic cells pulsed with the HLA-A2
restricted nonapeptide NLVPMVATV (NLV) derived from the cytomegalovirus-pp65 protein. These cyto-
toxic T cells have been given prophylactically to 9 recipients aged 4 to 65 years on or after day 28 post-
allogeneic hematopoietic stem cell transplant. Only 2 of 9 recipients received T cell depletion in vivo or in
vitro. There were no immediate adverse reactions to the infusions. During 97-798 days of follow-up, 2
recipients developed cytomegalovirus reactivation; neither developed cytomegalovirus disease or required
pharmacotherapy. Three recipients developed acute graft versus host disease after infusion. Two recipients
died, 1 from thrombotic thrombocytopenia purpura secondary to cyclosporine, 1 from complications of graft
versus host disease. A transient increase in numbers of cytomegalovirus-specific T cells demonstrated by
NLV-tetramer binding was seen in 6 recipients. Prophylactic adoptive transfer of NLV-specific T cells is safe
and may be effective in preventing cytomegalovirus reactivation.
© 2007 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) is curative for many malignant diseases.
owever, the procedure is complicated by prolonged
mmunodeﬁciency with the risk of life-threatening
nfections [1,2]. Cytomegalovirus (CMV) is a persis-
ent -herpes virus, present in the majority of the
opulation which reactivates in up to 70% of HSCT
ecipients at risk [3,4]. Although effective antiviral
rugs have decreased the incidence of CMV-related
isease and death, their efﬁcacy is limited by side lffects including marrow suppression and concomi-
ant opportunistic infections [5]. In addition, use of
hese drugs has led to an increase in late CMV disease
6]. Ultimately, CMV-speciﬁc immune reconstitution
ost effectively controls viral activation [7,8].
More than a decade ago, Riddell et al [9] described
he infusion of CMV-speciﬁc T cell clones derived
rom bone marrow donors to prevent CMV infection
osttransplant. Anti-CMV activity was seen to persist
n vivo for up to 4 weeks postinfusion, but the gener-
tion of these clones by limiting dilution cloning was
abor intensive and time consuming. Since then,
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K. Micklethwaite et al.708everal reports have described the efﬁcacy of CMV-
peciﬁc T cells in clearing active CMV infection
9-12]. These studies used a lysate of CMV infected
uman ﬁbroblasts to stimulate donor cytotoxic T-
ymphocytes (CTL) for the treatment of HSCT pa-
ients with CMV reactivation unresponsive to phar-
acotherapy. Expansion of CMV-speciﬁc cells in vivo
nd resolution of infection was reported in the major-
ty of cases studied.
There have been fewer reports of prophylactic
nfusion of CMV-speciﬁc T cells, and it remains un-
lear whether early administration of in vitro-gener-
ted CMV-speciﬁc CTL could be effective in prevent-
ng rather than treating CMV reactivation and
nfection post-HSCT. In the haploidentical transplant
etting of rigorous T cell depletion, Perruccio et al
13] infused small numbers of CMV-speciﬁc T cells
105 to 3  106/kg) 13 to 37 days posttransplant and
emonstrated lower rates of CMV reactivation com-
ared to controls. The Houston group infused tri-
irus-speciﬁc antigen-speciﬁc T cells generated using
pstein-Barr virus-transformed lymphocytes trans-
ected with an adenoviral vector encoding CMV pp65
rotein to 11 patients, 9 of whom had received in vivo
cell depletion prior to infusion of cells. Cells infused
ere seen to expand as measured by interferon-
LISPOT and tetramer analysis [14]. Since 2001, we
ave been recruiting HLA-A2-positive donor recipi-
nt pairs undergoing HSCT to a trial of prophylactic
MV-speciﬁc CTL infusion given at or beyond day
8 posttransplant. Using the HLA-A0201 restricted
p65 epitope NLVPMVATV (NLV) we generated
MV-speciﬁc T cells from 9 normal donors and in-
used them into recipients at or beyond 28 days post-
ransplant to determine the effect of prophylactic
MV-speciﬁc T cells in a group of mainly non-T
ell-depleted adult and pediatric transplant recipients.
ATIENTS AND METHODS
ntry Criteria and Patient and Donor Details
This phase I clinical safety trial was approved by
he institutional ethics committees of Westmead Hos-
ital and Children’s Hospital, Westmead.
Patients were enrolled into the study if they were
ndergoing allogeneic HSCT for hematologic malig-
ancy with HLA-A0201-positive, CMV seropositive
onors, and if they had HLA-identical or 1 antigen
ismatched donors. Recipient and donor characteris-
ics can be seen in Table 1.
Patients were excluded if they had a life expect-
ncy of 6 months.
Written informed consent was obtained from re-ipient and donor prior to enrollment. Ta Pa AA
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CMV-pp65 Peptide-Specific Cytotoxic T-Lymphocytes 709solation and Expansion of NLV-Specific T Cells
NLVPMVATV-speciﬁc T cells were generated as
reviously described [15]. Brieﬂy, peripheral blood
ononuclear cells (PBMC) were isolated from whole
lood (50-100 mL) by Ficoll gradient centrifugation
Amersham Biosciences, Uppsala, Sweden). Dendritic
ells were produced from monocytes isolated by ad-
erence. These were cultured for 7 days in RPMI
640 (Gibco, Grand Island, NY), supplemented with
% human AB serum (ARCBS, Sydney, Australia), rhu-
L-4 and rhu-GM-CSF 1000 U/mL (both from Cellge-
ix, Freiburg, Germany). Rhu-TNF- 200 U/mL
Chemicon International, Temecula, CA) was added to
nduce maturation on day 5. On day 7, monocyte
erived dendritic cells (MoDC) were pulsed with
LV peptide (Mimotopes, Clayton, Vic, Australia) 10
g/mL for 2 hours, washed, irradiated with 30 Gy,
nd used to stimulate T cell proliferation at a ratio of
:10. Stimulation was repeated on day 7 of culture
hen rhu-IL-2 (Chemicon International) 20 U/mL
as added. IL-2 concentration was increased to 50
/mL on day 14. Cells were harvested on day 21 and
ryopreserved. Cells were tested for Mycoplasma con-
amination and bacterial growth prior to infusion.
roducts infused were at least 60% viable as deter-
ined by trypan blue exclusion. In preclinical testing,
he alloreactivity of NLV-speciﬁc cells was tested
y lysis of third party PBMCs in chromium release
ssays. No lysis was found at E:T ratios of 100:1 or
elow. Two recipients in this study had their do-
or’s NLV-speciﬁc CTLs tested for alloreactivity
gainst recipient PHA blasts. No lysis was observed
t an E:T ratio of 40:1 or below.
mmunophenotyping and NLV-Tetramer Staining
Viable cells in the T cell culture were enumerated
y trypan blue exclusion and NLV-speciﬁc cells de-
ected by tetramer staining (Beckman Coulter, San
iego, CA). Phenotypic characteristics were deter-
ined by staining with the following antibodies: anti-
D3, anti-CD8, anti-CD4, anti-CD56, anti-CD19,
nti-CD62L, anti-CD45RA, and anti-CD45RO (Bec-
on Dickinson, San Jose, CA).
Postinfusion absolute tetramer T cell numbers
ere calculated by multiplying the NLV-tetramer
ercentage by the white cell count obtained from the
dvia full blood count analyzer. CD14, CD20, and
D56 cells binding tetramer nonspeciﬁcally were
xcluded using a single color exclusion gate.
For tetramer staining, cells were incubated at
oom temperature for 20 minutes in PBS/1% human
erum albumin (HSA) containing the PE-labeled tet-
americ complex, washed once, and resuspended in
BS/1% HSA. For surface antibody staining, cells
ere incubated at 4°C for 20 minutes in the presence
f respective antibodies, washed once, and resus- 1ended in PBS/1% HSA. A minimum of 10,000 cells
er sample were analyzed using a FACS Calibur with
ell Quest Software.
LV-Specific T Cell Infusion
All patients were treated on a regimen aiming at a
ose of 2 107/m2 cells. Cells were infused as a single
ose prophylactically on or after day 28 of the HSCT.
T cell infusion was deferred if the patient had any
f the following: grade II or greater graft versus host
isease (GVHD); was receiving steroids at a dose
quivalent to or greater than prednisolone 1 mg/kg/
ay within the last week; use of any broad spectrum
ymphocyte antibody (ATG, ALG, Campath) within 4
eeks of infusion or planned within the 4 weeks fol-
owing infusion; abnormal liver function (AST or ALT
3 times normal, total bilirubin 2 times normal) or
enal function (creatinine 2 times normal).
ostinfusion Enzyme-Linked Immunospot
ssay (ELISPOT)
Where possible, interferon- ELISPOT analysis
as carried out on recipient PBMC pre- and postin-
usion. Samples were cryopreserved and batched to
void interassay variability. ELISPOT was performed
n Multiscreen, MAIPS4510 96 well ﬁlter plates (Mil-
ipore, Bedford, MA) using catcher (m-AB 1-DIK)
nd detector (m-AB 7-B6-1-Biotin) antibodies
Mabtech, Billerica, MA), ExtrAvidin and SigmaFast
CIP/NBT alkaline phosphatase substrate (Sigma-
ldrich, St. Louis, MO) according to manufacturers’
irections. Cells per well (0.5 to 1  105) were sus-
ended in 200 L of AIMV supplemented with 10%
uman AB serum. These were stimulated for 20 hours
ith NLV peptide at 5 g/mL. Positive and negative
ontrols were cultured with PHA-L 5 g/mL or me-
ium alone. Spots were counted manually and results
xpressed as spot forming cells (SFC) per 105 cells.
MV Surveillance and Therapy
Standard institutional protocols for monitoring
nd preemptive therapy of CMV were followed. Quali-
ative CMV PCR was performed weekly. If positive,
uantitative CMV PCR was then performed and Gan-
iclovir 5mg/kg intravenously twice daily was initiated at
he discretion of the independent treating physician.
ESULTS
x Vivo Expansion of NLV-Specific T Cells
During 21 days of culture, NLV-speciﬁc T cells
xpanded from a baseline of 0.02% to 2.6% of PBMC
o constitute a median of 62% of ﬁnal cells (range
3%-95%). This represents 447 to 9717 fold expan-
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K. Micklethwaite et al.710ion (Table 2). In all cultures, the ﬁnal composition
ncluded CD3 cells 85%, CD56 cells 18%,
D14 and CD19 cells 2%. Phenotypic analysis
howed the T cells to have an effector-memory phe-
otype being CD62L	, CD45RO, and CD45RA	
Table 3).
Cultures for 3 patients (1, 3, and 4) failed to
xpand sufﬁciently to give the intended dose of 2 
07/m2. Doses of 0.06  107/m2, 0.4  107/m2, and
.9 107/m2 were given respectively to these patients.
afety of NLV-Specific T Cell Infusion
A total of 9 patients (6 CMV seropositive and 3
eronegative) received an NLV-speciﬁc T cell infu-
ion between days 28 and 86 post-HSCT (Tables 1
nd 4). Seven received nonmyeloablative and 2 my-
loablative conditioning (patients 1 and 8). No adverse
eaction occurred in the ensuing 24 hours. Patients
ave been followed up from 97-798 days postinfusion.
rogress postinfusion is summarized in Table 4.
etection of NLV-Specific T Cells Postinfusion
In 6 of the 9 recipients, a rise in NLV-speciﬁc T
ells within the ﬁrst 7 days could be demonstrated by
etramer staining (Figure 1). One CMV seronegative
ecipient (patient 2) had no detectable NLV-speciﬁc
cells prior to infusion. NLV-speciﬁc T cells were
resent in the peripheral blood within 2 hours of
able 2. Cell Expansion over 21 Days In vitro Culture
Patient
Starting Cell Count
Total Tetramer
1 2  106 0.4  103 0
2 2  106 22  103
3 11  106 22  103 1
4 16  106 48  103 4.
5 10  106 5  103 2
6 6  106 8.4  103 5
7 6  106 158.4  103 7
8 4  106 26.8  103
9 24  106 24  103
tarting and ﬁnal cell count refer to absolute numbers of total and
able 3. Final Phenotype of T Cell Cultures
Patient CD3 CD4 CD8 Tetramer
1 — 87 14 13
2 — 17.6 79 77
3 96.8 25.5 66.5 57.8
4 87 4 93 74.8
5 98.2 15.1 81.1 51
6 89 6.4 92.5 88
7 99 0 98 95
8 97 8.3 87.1 61.6
9 94 14 78 53
ll values show percentage of total cells except CD62L, CD45RO
ote: Memory phenotype unavailable for T cell cultures 1 and 2.nfusion and continued to be detectable for the fol-
owing 3 months (Figure 1A). The remaining 5 recip-
ents had NLV-speciﬁc T cells present at the time of
nfusion. The initial rise (median 1.85-fold, range
.68-8.00-fold) in absolute numbers of NLV-tet-
amer cells in the peripheral blood was followed by a
ecline to baseline levels over subsequent weeks (Fig-
re 1B and C).
Of the 3 recipients with no detectable increase, 2
ere CMV seronegative (patients 3 and 8) and 1 was
eropositive (patient 1). Patient 1 and patient 3 received
lower cell dose than intended as described above.
Two patients (recipients 7 and 9) had adequate
amples to perform detailed postinfusion interferon-
LISPOT analysis (Figure 1C). Recipient 7 demon-
trated an early rise in interferon- secreting cells
ollowed by a decline in SFC per 105 cells. This
attern approximated that of absolute NLV-tetramer
umbers. Recipient 9 also had an initial rise in SFC;
owever, this subsequently continued to rise in asso-
iation with a brief period of CMV PCR positivity not
equiring antiviral therapy. This pattern was divergent
rom that of the NLV-tetramer cell numbers that de-
reased to baseline levels within 1 month postinfusion.
ncidence of CMV Postinfusion
Two of 9 recipients had CMV reactivation postin-
usion. Patient 1 had CMV detectable by PCR once
Final Cell Count Fold Expansion
Tetramer Total Tetramer
07 0.65  106 2.5 1624
07 15.4  106 10 700
07 9.83  106 1.55 447
07 33.29  106 2.78 694
07 12.23  106 2.4 2446
07 47.52  106 9 5657
07 74.1  106 13 468
07 61.6  106 25 2299
07 233.2  106 18.33 9717
tetramer cells in culture.
62L CD45RO CD45RA CD19 CD56
— — — 1 4
— — — 1 6.8
7.7 97 0.7 0 1.6
3 96.5 1.2 0.5 16.7
3.3 94.2 8.6 0.6 1.1
0.5 98.5 0.8 0.5 1.4
7 99 0.5 0.3 1.6
2.1 99.1 2.1 0.7 1.6
6 96.9 1.3 1.9 3
D45RA, which show percentage of NLV-tetramer cells.Total
.5  1
2  1
.7  1
45  1
.4  1
.4  1
.8  1
10  1
44  1CD
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CMV-pp65 Peptide-Specific Cytotoxic T-Lymphocytes 711days postinfusion and again 47 days postinfusion.
n the second occasion, CMV positivity occurred 24
ours prior to death in the context of prednisolone 1.5
able 4. Postinfusion Progress
Patient
CTL Infusion
Day
Dose
Adverse
Reactions
CMV
Reactivation
107/m2 Y/N Y/N Da
1 69 0.06 N Y 116
2 40 2 N N —
3 29 0.4 N N —
4 33 1.9 N N —
5 86 2 N N —
6 63 2 N — —
7 28 2 N N —
8 31 2 N N —
9 65 2 N Y 90
Day” refers to day posttransplant; “Adverse Reactions” refers to
Infections” include bacterial, viral, or fungal infections at any tim
GVHD on 2 separate occasions (days 32 and 56) with complete
igure 1. In vivo detection of NLV-speciﬁc T cells postinfusion.
eripheral blood of recipient 2 immediately before infusion (ii), 4 h
ount (106/mL) and absolute number of NLV-tetramer T cells (
nd iii, respectively). (C) Total white cell count (106/mL), absolu
er 105 cells in recipients 7 and 9 (i and ii, respectively). Note: 29.2 a
ndicate infusion of CMV-speciﬁc T cells. CMV reactivation in recipientsg/kg/day for 2 days given for acute GVHD and
ultiorgan failure secondary to thrombotic thrombo-
ytopenia purpura (TTP) complicating cyclosporine
Postinfusion Progress
aGVHD
Non-CMV
Infections Death
Y/N Day Grade Y/N Y/N Day
Y 83 3 N Y 117
N — N N —
Y 32 56 2 3 Y N —
N — — N N —
N — — N N —
Y 74 3 N Y 86
N — — Y N —
N — — N N —
N — — N N —
lications arising within 24 hours of CTL infusion; “Non-CMV
transplant without evidence of CMV. Recipient 3 developed acute
tion between episodes.
V-tetramer T cells detectable in the infused cells (i) and in the
ostinfusion (iii), and 42 days postinfusion (iv). (B) Total white cell
L) within the ﬁrst weeks postinfusion in recipients 4, 5, and 6 (i, ii,
ber of NLV-tetramer T cells (104/mL), and interferon- SFC
on the x-axis labels denotes 2 hours postinfusion of T cells. Arrowsy
comp
e post(A) NL
ours p
104/m
te num
nd 65.26 and 9 is shown by hatched box.
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K. Micklethwaite et al.712herapy. Patient 9 had CMV detectable by qualitative,
ut not quantitative PCR 25 and 34 days postinfusion.
his required no therapy.
Because of a delay in the performance and notiﬁ-
ation of CMV testing, 1 recipient (patient 6) had
320 copies of CMV/mL present in the peripheral
lood at the time of infusion. Copy number fell to
ndetectable levels within 1 week of infusion, al-
hough qualitative PCR testing remained positive
Figure 1B[iii]).
None of the recipients developed CMV disease.
VHD Postinfusion
Three recipients aged 54, 62, and 65 years devel-
ped aGVHD postinfusion of NLV-speciﬁc T cells.
one had received in vivo or in vitro T cell depletion
f the stem cell product at the time of transplantation.
wo of these patients received transplants from
atched sibling donors, 1 from a 5 of 6 nonsibling
amily donor. In all 3 cases, GVHD had been present
efore the T cell infusion and onset of GVHD post-T
ell infusion was associated with reductions in corti-
osteroid dose (patient 1 and 6) or subtherapeutic
evels of cyclosporine A (patient 3).
Patient 1 had grade 2 GVHD of the skin 1 month
rior to T cell infusion. This was initially treated with
rednisolone 1.5 mg/kg/day followed by tapering to
.6 mg/kg/day at the time of the T cell infusion when
VHD had completely resolved. After the infusion,
he prednisolone dose was further decreased to 0.4
g/kg/day followed by the development of grade 3
VHD involving the gastrointestinal tract 14 days
ostinfusion.
Patient 3 had grade 1 GVHD of the skin at the
ime of T cell infusion. Grade 2 skin GVHD devel-
ped 3 days postinfusion associated with a subthera-
eutic cyclosporine level (63 ng/mL). Grade 3 gastro-
ntestinal GVHD developed 27 days postinfusion
ssociated with a reduction in prednisolone dose from
.8 mg/kg/day to 0.3 mg/kg/day.
Patient 6 had grade 2 GVHD of the skin 1 month
rior to cell infusion and was taking prednisolone 0.5
g/kg/day at the time of T cell infusion when GVHD
ad completely resolved. The dose of prednisolone
as reduced to 0.3 mg/kg/day 5 days postinfusion and
rade 3 gastrointestinal GVHD developed 11 days
ostinfusion.
Two recipients (patients 2 and 3) have subse-
uently developed cGVHD requiring low dose (10
g/day prednisolone) oral corticosteroids.
ther Adverse Events Postinfusion
Two of 9 patients died during follow-up. Patient 1
ied of thrombotic thrombocytopenic purpura related
o high cyclosporine levels 48 days postinfusion. Pa- sient 6 died of perforated bowel complicating acute
astrointestinal GVHD 23 days postinfusion.
Patient 3 had hemorrhagic cystitis associated with
olyoma virus at the time of infusion. Patient 7 had a
ransient elevation in liver enzymes 14 days postinfu-
ion in the context of past hepatic candidiasis with
ersistent radiologic abnormalities. Patient 7 also had
n episode of central venous catheter associated sep-
icemia necessitating catheter removal 88 days postin-
usion.
ISCUSSION
We recruited 9 patients to a phase I safety trial of
doptive immunotherapy of CMV-speciﬁc T cells. In
ontrast to other studies of CMV-speciﬁc immuno-
herapy, our trial explored a prophylactic immuno-
herapy strategy in adult and pediatric transplant re-
ipients who had mostly undergone nonmyeloablative
SCT without in vitro or in vivo T cell depletion.
e utilized a simple and rapid method for generating
cells reactive to the HLA-A2-restricted NLV
pitope of the CMV-pp65 protein that were given on
r after day 28 of HSCT. Over 21 days of culture,
e saw 447- to 9717-fold expansion of NLV-speciﬁc
ells in vitro. Cultures consisted mainly of T cells with
ittle contamination by B cells or monocytes.
No toxicity was seen within 24 hours of infusion in
ny of the 9 patients. Infusion of the cells was followed
y a rise in NLV-tetramer cells in the peripheral
lood in 6 of 9 recipients. Of the 3 others, 2 received
lower dose of T cells at the initiation of the study
nd 2 were CMV seronegative. Five of the 6 recipients
ho had a demonstrable rise in NLV-speciﬁc T cells
ad NLV-tetramer binding cells present prior to in-
usion. We and others have previously observed that
MV reactivation post-HSCT is associated with an
ncrease in dysfunctional CMV-speciﬁc T cells rather
han numeric deﬁciency [16]. We have frequently ob-
erved that NLV-tetramer cells are present in the
irculation at highest number following nonmyeloab-
ative T cell replete HSCT immediately prior to
MV reactivation. The infusion of ex vivo expanded
ntigen-speciﬁc T cells may provide the functional
ctivity required to prevent CMV infection.
Previous studies using CMV-speciﬁc T cells given
or CMV infection have demonstrated in vivo cell
xpansion. Although we saw an early rise in absolute
umbers of NLV-speciﬁc T cells in 6 of 9 recipients,
ises were modest and did not persist beyond several
ays to weeks. There are several possible reasons for
his: (1) the absence of antigenic stimulus required for
roliferation; (2) exhaustion of the antigen-speciﬁc T
ells during their in vitro expansion; (3) the lack of
ntigen-speciﬁc CD4 T cells to provide the neces-
ary help for expansion; (4) suppression of prolifera-
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CMV-pp65 Peptide-Specific Cytotoxic T-Lymphocytes 713ion of NLV-speciﬁc T cells by the T cell repertoire
lready established in the nonmyeloablative setting.
ne patient (recipient 9) developed a brief and self-
imited episode of CMV reactivation several days after
eceiving NLV-speciﬁc T cells. Interferon- produc-
ng cells in this recipient remained elevated during
his period, suggesting that the presence of a greater
uantity of antigen may be important for cell expan-
ion.
Three patients aged 54, 62, and 65 years receiving
on-T cell-depleted allografts developed GVHD
ithin 14 days of receiving CMV-speciﬁc T cells and
patient died from GVHD. One of these patients had
eceived a transplant from a 1 antigen mismatched
onsibling family donor. All had had GVHD prior to
nfusion of CMV-speciﬁc T cells. This rate of GVHD
s similar to that which we have observed in a group of
atients transplanted concurrently using a similar con-
itioning regimen but not receiving T cell infusions
17]. We cannot exclude the possibility that CMV-
peciﬁc CTL caused or exacerbated GVHD in these
atients, although in each case, onset of GVHD was
ssociated with a reduction in corticosteroid dosage by
he independent treating physician or a documented
ubtherapeutic level of cyclosporine. Antigen-speciﬁc
cell therapy would ideally be given in conjunction
ith depletion of nonspeciﬁc T cells at the time of
ransplantation. However, until a wider range of in-
ectious and malignant T cell antigens can be targeted,
e have elected to continue to infuse unmanipulated
tem cells. Despite this, caution is clearly necessary in
dministration of donor T-cells in the context of al-
ogeneic HSCT, particularly in older patients and in
hose with prior GVHD. In particular, we have
dopted as a release criterion for CTL the lack of
lloreactivity as demonstrated by 10% killing of
ecipient PHA blasts at an E:T ratio of 40:1 in a
hromium release assay. We had initially relied on
emonstrating that expanded CMV-speciﬁc CTL
ailed to respond to third party cells. However, more
igorous and individualized testing is clearly required
o reduce the possibility of inducing or exacerbating
VHD. We have also subsequently amended our pro-
ocol to ensure only gradual reductions in corticoste-
oid and immunosuppressive dosage following T cell
nfusions in patients receiving steroids at the time of T
ell infusion.
Two of 9 patients in our study reactivated CMV,
while receiving high-dose corticosteroids (known to
dversely affect the survival of infused lymphocytes)
18] and the other as a brief self-limited reactivation
ot requiring speciﬁc therapy. The reported overall
eactivation rate of CMV in several recent series varies
rom 40%-70% [2-4,7] with a reactivation rate up to
0% in high-risk patients. Reconstitution of reactivity
o 1 epitope of pp65 may not be adequate to prevent
eactivation or infection of CMV. Indeed, at leaststudy suggests that reactivity to other epitopes such
s IE-1 may be at least if not more important than
p65 reactivity in preventing CMV disease in some
ransplant settings [19]. Our data do not allow us to
raw conclusions regarding the efﬁcacy of our pro-
hylactic CMV-speciﬁc T cell infusions post-HSCT.
larger and randomized study will be required for
hat purpose. As a result of the HLA restrictions
nherent in using a single peptide epitope, we recently
pened a prophylaxis study of CMV-speciﬁc T cells
ost-HSCT utilizing an adenoviral vector encoding
he CMV-pp65 protein to transduce dendritic cells for
he purpose of raising T cells. A multiepitope immune
esponse may provide more extensive immune surveil-
ance, whereas the removal of the HLA restriction will
ssist in more rapid recruitment to efﬁcacy studies.
he current study demonstrates the short-term safety
f infused NLV-speciﬁc T cells, limited T cell expan-
ion in vivo and favorable rates of CMV reactivation
ompared to historic controls. Efﬁcacy studies exam-
ning rates of CMV reactivation following prophylac-
ic infusion of CMV-speciﬁc T cells will ultimately
etermine the place of this form of therapy in alloge-
eic HSCT.
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